Observational Copenhagen Pancreatic Cancer Study

NCT ID: NCT06713525

Last Updated: 2024-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

8000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-31

Study Completion Date

2036-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study objective is to describe the real-world population of patients with pancreatic cancer by collecting longitudinal data that facilitates a more rigorous understanding of the PC. This research project will catalog different elements of a patient's diagnostic and treatment journey and identify unmet needs of patients with PC.

The study aims to:

1. To compile detailed demographic information of patients with PC.
2. To document and analyze the clinical and disease characteristics at the time of diagnosis and beyond.
3. To track various treatment modalities employed, including surgery, chemotherapy, and radiation therapy.
4. To assess short-term and long-term outcomes, including survival rates, complications, and quality of life.
5. To identify prognostic and predictive factors within the real-world cohort.

8\. To investigate the impact of PC and treatment on patients' quality of life.

4 Study Design This study of patients with PC will employ both a prospective, observational design and retrospective design to capture real-world data relating to health status and/or the delivery of health care routinely collected from a variety of sources. Data will be collected longitudinally, allowing for a dynamic analysis of the disease trajectory.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with PC are referred to Comprehensive Pancreatic Cancer Center at Herlev Hospital

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Histologically confirmed pancreatic cancer

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inna Chen, MD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Inna Chen, MD

MD

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Inna Markovna Inna Markovna Chen, MD, Herlev & Gentofte Hospital, MD

Role: CONTACT

+45 3868-2898

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PA2416

Identifier Type: -

Identifier Source: org_study_id